Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer (PRESERVE)

10 settembre 2026 aggiornato da: University of Utah

PRESERVE: A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer

The purpose of this study is to evaluate whether Enfortumab Vedotin in combination with Pembrolizumab can achieve a clinical response that preserves the bladder and avoids the need for cystectomy or radiation therapy in patients with urothelial cancer.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

25

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Participant aged ≥ 18 years.
  • Disease criteria:

    • Histologically confirmed muscle-invasive urothelial carcinoma (T2-T3N0M0) without small cell variant histology of bladder. Other variant histologies are allowed if urothelial histology is present.
    • No evidence of local or distant metastasis on CT scans.
    • Urothelial carcinomas not originating from the bladder (eg, upper tract [ureters, renal pelvis], urethra) are not eligible.
  • Eligible to receive enfortumab vedotin and pembrolizumab.
  • ECOG Performance Status ≤ 2.
  • Adequate organ function as defined as:

    • Hematologic:

      • Absolute neutrophil count ≥ 1500/mm3
      • Platelet count ≥ 100,000/mm3
      • Hemoglobin ≥ 10 g/dL
    • Hepatic:

      • Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN), ≤3× ULN for subjects with suspected Gilbert's syndrome with direct bilirubin ≤ ULN.

        ----AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN

      • Renal:

        • Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula (or measured by 24-hour urine collection).
  • Participants must adhere to the following sex and contraceptive/barrier requirements:

    • If participant is of childbearing potential, they must have a negative pregnancy test.
    • For participants of non-childbearing potential: The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:
    • < 50 years of age:

      • Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and
      • Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution

        --≥ 50 years of age:

      • Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or
      • Had radiation-induced menopause with last menses >1 year ago; or
      • Had chemotherapy-induced menopause with last menses >1 year ago
      • Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution
    • Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception and lactation requirements as described in Sections 5.4.2 and 5.4.3.
  • Clinically significant adverse effects from any prior oncologic treatment (e.g. prior surgery, radiotherapy, or other antineoplastic therapy) must have resolved or have been determined to be clinically stable per the Investigator.
  • Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
  • Participant has been counseled on standard of care treatment options available to them and has expressed they are interested in pursuing bladder preservation without cystectomy or radiation.

The discussion regarding the choice of standard therapy offered, if available, and patient's choice to decline standard therapy should be documented clearly in the research chart.

Exclusion Criteria:

  • Prior systemic therapy for urothelial cancer.
  • Receiving other systemic investigational agents for urothelial cancer.
  • Hemoglobin A1c > 8% or 7-8% with associated diabetes symptoms.
  • Autoimmune disease requiring systemic steroids or immunosuppressive agents in the last 2 years.
  • Neuropathy Grade ≥2.
  • Prior radiotherapy for urothelial cancer.
  • Major surgery within 4 weeks prior to starting study therapy or participant has not fully recovered from major surgery per clinical investigator.
  • The diagnosis of another malignancy which, in the opinion of the Investigator, is likely to negatively impact study objectives or the participant's safety or ability to participate in the study.
  • Known metastatic disease.
  • Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:

    • Cardiovascular disorders:

      • Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias per clinical investigator.
      • Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other significant ischemic events per clinical investigator, within 3 months before the first dose. Subjects with pulmonary embolism or deep vein thrombosis if adequately managed can be enrolled.
    • Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, social/ psychological issues, etc.)
  • Active infection expected to interfere with study treatment in the opinion of the investigator.
  • Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment.

    --Note: Participants on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.

  • Hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C.

Note: Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Participants positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

  • Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.
  • Known prior severe hypersensitivity to investigational product or any component in its formulations (CTCAE v6.0 Grade ≥ 3).
  • Participants taking prohibited medications as described in Section 6.8.2.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment: All Patients
All patients will be treated with enfortumab vedotin in combination with pembrolizumab.
Enfortumab vedotin 1.25 mg/kg, IV on days 1 and 8 on a 21day cycle for 9 cycles
Subjects will receive one year of treatment with pembrolizumab IV or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) SC. Treatment will be administered per institutional standards every 3 weeks or 6 weeks, at the physician's discretion.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
cT0 or cTa low-grade disease as assessed by cystoscopy and bladder biopsy, including all visually abnormal sites in addition to reTURBT or biopsy of the known site of MIBC before neo- adjuvant therapy
Lasso di tempo: 6 years
To assess the proportion of patients who have achieved a clinical complete response and have maintained bladder preservation without undergoing definitive treatment of cystectomy or radiation after 4 cycles of study treatment.
6 years
Negative tumor-informed ctDNA
Lasso di tempo: 6 years
To assess the proportion of patients who have achieved a clinical complete response and have maintained bladder preservation without undergoing definitive treatment of cystectomy or radiation after 4 cycles of study treatment.
6 years
The absence of malignant cells on urine cytology
Lasso di tempo: 6 years
To assess the proportion of patients who have achieved a clinical complete response and have maintained bladder preservation without undergoing definitive treatment of cystectomy or radiation after 4 cycles of study treatment.
6 years
No definitive evidence of new local or metastatic disease at cross-sectional imaging per investigator judgement
Lasso di tempo: 6 years
To assess the proportion of patients who have achieved a clinical complete response and have maintained bladder preservation without undergoing definitive treatment of cystectomy or radiation after 4 cycles of study treatment.
6 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type.
Lasso di tempo: 6 years
To assess the safety and tolerability of enfortumab vedotin in combination with pembrolizumab in the study population.
6 years
The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by severity (as defined by the NIH CTCAE, version 6.0).
Lasso di tempo: 6 years
To assess the safety and tolerability of enfortumab vedotin in combination with pembrolizumab in the study population.
6 years
The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness.
Lasso di tempo: 6 years
To assess the safety and tolerability of enfortumab vedotin in combination with pembrolizumab in the study population.
6 years
The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by duration.
Lasso di tempo: 6 years
To assess the safety and tolerability of enfortumab vedotin in combination with pembrolizumab in the study population.
6 years
The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by their relationship to the study treatment.
Lasso di tempo: 6 years
To assess the safety and tolerability of enfortumab vedotin in combination with pembrolizumab in the study population.
6 years
Residual or recurrent MIBC, as assessed by biopsy
Lasso di tempo: 6 years

To assess bladder intact event-free survival (EFS), defined as the time from treatment initiation to the first occurrence of any of the following events:

  1. residual or recurrent MIBC, as assessed by biopsy;
  2. local or distant disease (N1, N2, N3 or M1) disease as confirmed histologically or as assessed by imaging if biopsy is not feasible due to safety concerns;
  3. cystectomy or radiation to bladder;
  4. death from any cause
6 years
Local or distant disease (N1, N2, N3 or M1) disease as confirmed histologically or as assessed by imaging if biopsy is not feasible due to safety concerns.
Lasso di tempo: 6 years

To assess bladder intact event-free survival (EFS), defined as the time from treatment initiation to the first occurrence of any of the following events:

  1. residual or recurrent MIBC, as assessed by biopsy;
  2. local or distant disease (N1, N2, N3 or M1) disease as confirmed histologically or as assessed by imaging if biopsy is not feasible due to safety concerns;
  3. cystectomy or radiation to bladder;
  4. death from any cause
6 years
Cystectomy or radiation to bladder
Lasso di tempo: 6 years

To assess bladder intact event-free survival (EFS), defined as the time from treatment initiation to the first occurrence of any of the following events:

  1. residual or recurrent MIBC, as assessed by biopsy;
  2. local or distant disease (N1, N2, N3 or M1) disease as confirmed histologically or as assessed by imaging if biopsy is not feasible due to safety concerns;
  3. cystectomy or radiation to bladder;
  4. death from any cause
6 years
Death from any cause
Lasso di tempo: 6 years

To assess bladder intact event-free survival (EFS), defined as the time from treatment initiation to the first occurrence of any of the following events:

  1. residual or recurrent MIBC, as assessed by biopsy;
  2. local or distant disease (N1, N2, N3 or M1) disease as confirmed histologically or as assessed by imaging if biopsy is not feasible due to safety concerns;
  3. cystectomy or radiation to bladder;
  4. death from any cause
6 years
The time to NMIBC defined as the time from treatment initiation to the first occurrence of NMIBC (cTa, cT1, or carcinoma in situ) as assessed by biopsy.
Lasso di tempo: 6 years
To assess time to non-muscle invasive bladder cancer (NMIBC) defined as the time from treatment initiation to the first occurrence of NMIBC (cTa, cT1, or carcinoma in situ) as assessed by biopsy.
6 years
Local or distant disease (N1, N2, N3 or M1) disease as confirmed histologically or as assessed by imaging if biopsy is not feasible due to safety concerns.
Lasso di tempo: 6 years

To assess distant disease-free survival (DDFS) defined as the time from treatment initiation to the first occurrence of any of the following events:

  1. local or distant disease (N1, N2, N3 or M1) disease as confirmed histologically or as assessed by imaging if biopsy is not feasible due to safety concerns;
  2. death from any cause
6 years
Death from any cause
Lasso di tempo: 6 years

To assess distant disease-free survival (DDFS) defined as the time from treatment initiation to the first occurrence of any of the following events:

  1. local or distant disease (N1, N2, N3 or M1) disease as confirmed histologically or as assessed by imaging if biopsy is not feasible due to safety concerns;
  2. death from any cause
6 years
Overall survival (OS) as defined as the time from initiation of treatment until death from any cause.
Lasso di tempo: 6 years
To assess overall survival in this study population.
6 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 novembre 2034

Completamento dello studio (Stimato)

1 novembre 2035

Date di iscrizione allo studio

Primo inviato

10 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

10 settembre 2026

Primo Inserito (Effettivo)

16 settembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • HCI205161

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi